Science News

... from universities, journals, and other research organizations

Not All Stem Cells Are Equally Efficient for Use in Regenerative Medicine

Jan. 9, 2013 — Scientists at the University of Granada and Alcalá de Henares University have found out that not all isolated stem cells are equally valid in regenerative medicine and tissue engineering. In a paper recently published in the journal Tissue Engineering the researchers report that, contrary to what was thought, only a specific group of cord blood stem cells (CB-SC) maintained in culture are useful for therapeutic purposes.


Share This:

At present, CB-SCs are key to regenerative medicine and tissue engineering. From all types of CB-SC those called "Wharton's jelly stem cells (HWJSC)" are stirring up the interest of specialists in regenerative medicine, due to their accessibility and great ability to develop into several types of tissue and modulate immune responses.

Through a combination of microscopy and microanalysis essays, and the study of the genes involved in cell viability, the researchers discovered that only a specific group of cord blood stem cells (CB-SC) maintained in culture is useful for therapeutic purposes

The Most Suitable Cells

The relevance of this paper, which was the cover article in the journal Tissue Engineering, lies in the possibility to select the most suitable HWJSC for tissue engineering and regenerative medicine. According to these researchers, the different studies with HWJSC have obtained contradictory results because researchers failed to previously select the most suitable cell group.

The results of this study also open the possibility to select stem cell subgroups from different tissues, in order to improve the therapeutical efficacy of different regenerative medicine protocols.

This research study was conducted by the Tissue Engineering research group at the University of Granada Histology Department coordinated by professor Antonio Campos Muñoz, who recently created artificial skin and a cornea by using stem cells and new biomaterials developed in Granada.

The research group is also composed of professors Alaminos Mingorance and Ingrid Garzón. Professor Garzon was awarded a prize at the World Congress on Tissue Engineering and Regenerative Medicine held in Seul for a preliminary study on the same issue.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

|

Story Source:

The above story is reprinted from materials provided by University of Granada, via AlphaGalileo.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Ingrid Garzón, Barbara Pérez-Köhler, Juan Garrido-Gómez, Victor Carriel, Renato Nieto-Aguilar, Miguel Angel Martín-Piedra, Natalio García-Honduvilla, Julia Buján, Antonio Campos, Miguel Alaminos. Evaluation of the Cell Viability of Human Wharton's Jelly Stem Cells for Use in Cell Therapy. Tissue Engineering Part C: Methods, 2012; 18 (6): 408 DOI: 10.1089/ten.TEC.2011.0508
APA

MLA

Note: If no author is given, the source is cited instead.

Search ScienceDaily

Number of stories in archives: 137,193

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily's archives for related news topics,
the latest news stories, reference articles, science videos, images, and books.

Recommend ScienceDaily on Facebook, Twitter, and Google:

Other social bookmarking and sharing services:

|

 
  more breaking science news

Social Networks


Recommend ScienceDaily on Facebook, Twitter, and Google +1:

Other social bookmarking and sharing tools:

|

Breaking News

... from NewsDaily.com

In Other News ...

Science Video News


Unraveling Brain Tumors

Brain tumor researchers have found that brain tumors arise from cancer stem cells living within tiny protective areas formed by blood vessels in the. ...  > full story

Strange Science News

 

Free Subscriptions

... from ScienceDaily

Get the latest science news with our free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Feedback

... we want to hear from you!

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?

Post this page to your favorite social bookmarking site:
Include this item in your blog or web site:
Cite this article in your essay, paper, or report:
Email this page's link to a friend or colleague: